Metrospine PC
Metrospine PC was paid $4.88M by Medicaid between Jan 2018 and Dec 2024, across 52 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 36% of everything it billed.
33Billing provider infoMETROSPINE PC
OXON HILL, MD 20745
OXON HILL, MD 20745
33aNPI1194844357assigned 03/28/2007
33bProvider typeSpecialist
28Total paid$4.88M
24GClaims97,741
24DCodes billed52
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in Maryland
Rank by total paid#7 of 218
Median peer was paid$88K
This provider vs. median56×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,019 | $473K | |
| 2019 | 16,611 | $738K | |
| 2020 | 18,124 | $858K | |
| 2021 | 15,523 | $770K | |
| 2022 | 13,208 | $775K | |
| 2023 | 11,715 | $645K | |
| 2024incomplete | 8,541 | $619K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 36% | 30,615 | 28,209 | $1.77M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 23% | 14,493 | 13,391 | $1.12M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 22% | 9,631 | 9,111 | $1.06M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 7.3% | 3,701 | 3,500 | $357K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.7% | 1,078 | 1,018 | $132K |
| 80305 | 1.8% | 12,055 | 11,406 | $88K | |
| 20611 | 1.5% | 1,061 | 964 | $74K | |
| 64493 | 1.1% | 415 | 392 | $53K | |
| 64483 | 1.0% | 274 | 262 | $49K | |
| 93922 | <1% | 502 | 487 | $38K | |
| 95923 | <1% | 383 | 371 | $29K | |
| 95921 | <1% | 381 | 369 | $20K |
40 more codes
| 64494 | <1% | 371 | $15K | |
| 64495 | <1% | 332 | $14K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,206 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 322 | $6K |
| 64484 | <1% | 109 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 165 | $5K |
| 20610 | <1% | 73 | $4K | |
| 99439 | <1% | 556 | $4K | |
| 96132 | <1% | 82 | $4K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 117 | $4K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 17 | $2K |
| A4657 | Syringe, with or without needle, each | <1% | 2,798 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 111 | $2K |
| 62323 | <1% | 13 | $2K | |
| 97750 | <1% | 89 | $2K | |
| A6220 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 3,039 | $2K |
| 95911 | <1% | 13 | $2K | |
| 96138 | <1% | 35 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 59 | $1K |
| 97035 | <1% | 110 | $879.65 | |
| 96004 | <1% | 15 | $834.08 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 967 | $819.73 |
| 95886 | <1% | 15 | $690.64 | |
| A4215 | Needle, sterile, any size, each | <1% | 3,583 | $485.16 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 867 | $346.90 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,501 | $237.28 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,797 | $207.89 |
| 96127 | <1% | 21 | $139.14 | |
| 99490 | Ccm add 20min | <1% | 556 | $45.60 |
| 96130 | <1% | 37 | $31.64 | |
| 83992 | <1% | 51 | $15.90 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,695 | $15.10 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 78 | $2.39 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 80 | $2.24 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 78 | $0.51 |
| 99487 | Ccm add 20min | 0% | 18 | $0.00 |
| 99457 | 0% | 96 | $0.00 | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 0% | 35 | $0.00 |
| 99489 | Ccm add 20min | 0% | 18 | $0.00 |
| 99458 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDRAKES, GEORGE (CEO)
| Provider | Location | Paid |
|---|---|---|
| Metrospine PC | Clinton, MD | $430K |
| Metrospine PC | Clinton, MD | $351K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.